Publicaciones en las que colabora con Beatriz Ballester Rodríguez (14)

2022

  1. The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates with transforming growth factor β inducing fibrotic responses

    Mucosal Immunology, Vol. 14, Núm. 2, pp. 377-388

  2. Muc16 is overexpressed in idiopathic pulmonary fibrosis and induces fibrotic responses mediated by transforming growth factor-β1 canonical pathway

    International Journal of Molecular Sciences, Vol. 22, Núm. 12

  3. The role of mucin 1 in respiratory diseases

    European Respiratory Review, Vol. 30, Núm. 159, pp. 1-18

2020

  1. Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation

    Oncotarget, Vol. 11, Núm. 15, pp. 1306-1320

2019

  1. Idiopathic pulmonary fibrosis and lung cancer: Mechanisms and molecular targets

    International Journal of Molecular Sciences, Vol. 20, Núm. 3

  2. MUC1 intracellular bioactivation mediates lung fibrosis

    Thorax, Vol. 75, Núm. 2, pp. 132-142

  3. Mucins as a new frontier in pulmonary fibrosis

    Journal of Clinical Medicine, Vol. 8, Núm. 9

2018

  1. JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study

    Thorax, Vol. 73, Núm. 6, pp. 519-529

  2. MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology

    Respiratory Research, Vol. 19, Núm. 1

  3. The JAK2 pathway is activated in idiopathic pulmonary fibrosis

    Respiratory Research, Vol. 19, Núm. 1

2017

  1. MUC4 impairs the anti-inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps

    Journal of Allergy and Clinical Immunology, Vol. 139, Núm. 3, pp. 855-862.e13

2016

  1. Molecular based drug targets for idiopathic pulmonary fibrosis

    Current Respiratory Medicine Reviews, Vol. 12, Núm. 3, pp. 186-207

2015

  1. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist

    Respiratory Research, Vol. 16, Núm. 1